BIB

ProShares Ultra Nasdaq Biotechnology [BIB] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

BIB Stock Summary

Top 10 Correlated ETFs

BIB

Top 10 Correlated Stocks

BIB

In the News

BIB Financial details

Company Rating
-
Market Cap
92.09M
Income
-
Revenue
-
Book val./share
-
Cash/share
-
Dividend
0.04
Dividend %
0.06%
Employees
-
Optionable
No
Shortable
Yes
Earnings
-
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
10.81%
SMA50
23.91%
SMA100
47.57%
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
40.1-62.45
52W High
+10.15%
52W Low
+70.73%
RSI
57.95
Rel Volume
0.08
Avg Volume
42.32K
Volume
3.27K
Perf Week
1.96%
Perf Month
17.64%
Perf Quarter
71.41%
Perf Half Y
45.58%
-
-
-
-
Beta
1.31
-
-
Volatility
0.95%, 4.01%
Prev Close
-1.95%
Price
68.2901
Change
-4.3%

BIB Financial Performance

BIB Dividend History

BIB Frequently Asked Questions

What is ProShares Ultra Nasdaq Biotechnology stock symbol ?

ProShares Ultra Nasdaq Biotechnology is a US stock and trading under the symbol BIB

What is ProShares Ultra Nasdaq Biotechnology stock quote today ?

ProShares Ultra Nasdaq Biotechnology stock price is $68.2901 today.

Is ProShares Ultra Nasdaq Biotechnology stock public?

Yes, ProShares Ultra Nasdaq Biotechnology is a publicly traded company.

Something similar

Top by Market Cap
TL0.DE
1YD.DE
AMZ.DE
BRK-B
MSF.DE
Top Correlated ETFs
IBB
IBBQ
BTEC.L
SBIO.L
BTEE.L
Top Correlated Stocks
FSPHX
FBIOX
ARGX
ARGX.BR
SHSCX
Similar Market Cap
2146.HK
QUS.TO
GAMCU
8036.HK
1529.HK

Company Profile

Financial Services Asset Management
  • Volume Average 42.32K
  • Market Capitalization 92.09M
  • Headquarters US
  • IPO Date 2010-04-09

The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.